A comparative study of mebeverine and synbiotic combination in patients with diarrhoea predominant Irritable Bowel Syndrome in a Medical College in South India
Keywords:Irritable bowel syndrome, Probiotic, Synbiotic
Background: Irritable bowel syndrome (IBS) is a chronic, episodic functional gastrointestinal disorder characterized by abdominal pain / discomfort and altered bowel habits. Though it is considered as a functional disorder, the burden of the disease to the patients is very high and the quality of life becomes miserable. Currently available IBS therapies are mainly symptom oriented and have limited efficacy. Various studies had done so far which provide a clear rationale for the use of Synbiotic in this disorder. The objective of the study includes, this study was planned to compare the efficacy of Mebeverine + Synbiotic combination with Mebeverine and Synbiotic monotherapy in patients with diarrhoea predominant irritable bowel syndrome.
Methods: The study was done in Department of Medical Gastroenterology, Rajiv Gandhi Government Hospital, Chennai for duration of one year. Patients with Irritable Bowel Syndrome (diarrhea predominant type), diagnosed within 1 year and attending outpatient department were taken. A randomized, Phase III, prospective, interventional, open label, outpatient, comparative study design was done. A total of 60 patients divided into 3 groups were finally selected for the study purpose.
Results: Twelve weeks after completion of active drug therapy, the Mebeverine + Synbiotic combination improved all the symptoms of IBS except abdominal pain. Further it was evident that combination therapy had significant remission in stool frequency and consistency when compared with other groups.
Conclusions: Combination of Mebeverine + Synbiotic is more effective in improving most of the troublesome symptoms in patients with diarrhea predominant irritable bowel syndrome than other therapies and also in maintaining remission, in terms of frequency and consistency of stools.
Hahn BA, Yan S, Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion. 1999;60(1):77-81.
Malinen E, Rintilla T, Kajander K, Matto J, Kassinen A, Krogius L, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. The American journal of gastroenterology. 2005;100(2):373-82.
King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable Bowel syndrome. Lancet. 1998;352(9135):1187-9.
Treem WR, Ashan N, Kastoff G, Hyams JS. Fecal short chain fatty acids in patients with diarrhea predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. Journal of pediatric gastroenterology and nutrition. 1996;23(3):280-6.
Chey WY, Jin HO, Lee MH. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. AmJ Gastroenterol. 2001;96:1499-506.
Clemens CH, Samson M, Roelofs JM. Association between pain episodes and high amplitude propagated pressure waves in patients with irritable bowel syndrome AmJ Gastroenterol. 2003;98:1838-43.
Kingham JGC, Bown R, Colson R, Clark ML. Jejunal motility in patients with functional abdominal pain. Gut. 1984;25:375.
Sharkey KA, Wallace JL. Treatment of bowel motility disorders. In: Laurence Brunton, Bruce Chabner, Bjorn Knollman (eds) Goodman and Gilman’s, The pharmacological basis of therapeutics, 12th ed:1339-1343.
Colin Drollery. Therapeutic Drugs 2nd edition. Churchill Livingston. 1999;1:M15-7.